Head and Neck Cancer

PV QA 2 - Poster Viewing Q&A 2

MO_31_2728 - Evaluation of Induction Chemotherapy with EPF or TPF for Patients with Locally Advanced Nasopharyngeal Carcinoma

Monday, October 22
10:45 AM - 12:15 PM
Location: Innovation Hub, Exhibit Hall 3

Evaluation of Induction Chemotherapy with EPF or TPF for Patients with Locally Advanced Nasopharyngeal Carcinoma
X. Peng1, L. Wang2, Z. Wei3, and P. Li4; 1State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China, 2Cancer center, west china hospital, sichuan university, chengdu, China, 3Cancer Center, West China Hospital, Sichuan University, Chengdu, China, 4Cancer center, west china hospital, sichuan university, Chengdu, China

Purpose/Objective(s): We performed this match-paired study to compare the efficacy, toxicities and pharmacoeconomics between EPF regimes (Epirubicin 40mg/m2 d1; Cisplatin 60mg/m2 d1; and Fluorouracil 2000mg/m2 d1,8,15) and TPF regimes (Docetaxel 75mg mg/m2 d1; Cisplatin 75 mg/m2 d1 and fluorouracil 750 mg/m2 d1-5) as induction chemotherapy for locally advanced nasopharyngeal carcinoma (NPC), in order to optimize the regimes induction chemotherapy for nasopharyngeal carcinoma patients.

Materials/Methods: We prospectively did the clinical study to compare the treatment results and side effects between EPF regimes and TPF regimes as induction chemotherapy for the patients with locally advanced NPC hospitalized in West China Hospital of Sichuan University Cancer Center from May 1, 2016 to December 31, 2016. Inclusion criteria: age ranges from 18 to 70; ECOG physical performance score≤ 1; patients with NPC were pathologically confirmed in our hospital; Clinical stage with III-IVb according to the seventh edition of AJCC staging criteria. Exclusion criteria: patients younger than 18 or older than 70; ECOG score >1; patients has a second primary tumor or previous history of malignant tumors; liver and kidney dysfunction (AST, ALT more than 2.5 times normal limits; BUN more than 1.5 times normal limits); patients with cardiac function decrease (EF ≤55% ); poor patient compliance. Eligible patients were given EPF regimes as induction chemotherapy. Meanwhile, we retrospectively analyzed patients with NPC treated in our hospital with TPF regimes as induction chemotherapy from May 1, 2011 to December 31, 2016. All the patients were matched by gender, age, stage, and ECOG score in both EPF and TPF regimes. Objective response was performed by chi-square test. Paired rank test was used to compare toxicities between two groups.

Results: 40 patients were included in this study. Among the 40 patients, 30 were male, 10 were female. The ratio of male and female was 3: 1. Age ranges from 19 to 59 years old, with an average age of 43 years. According to the seventh edition of NPC UICC/AJCC stage classification, there were 18 cases, 11 cases and 11 cases in III, IVa and IVb stage respectively. All patients performance status were 0-1 points in criteria of ECOG. 20 patients were included in EPF group, and the other 20 patients in TPF group. The objective response rates of was significant higher comparing EPF group to TPF group(80% VS.50%,P<0.050). In terms of toxicity, there was no statistically different between EPF group and TPF group.

Conclusion: Treatment with EPF regime as induction chemotherapy for locally advanced nasopharyngeal carcinoma was shown higher objective response rate than that TPF regime, without significant difference in toxicities comparing both regimes. This study provides a new choice induction chemotherapy regime for locally advanced nasopharyngeal, and also laid the foundation for the further phase III clinical research.

Author Disclosure: X. Peng: None. Z. Wei: None. P. Li: None.

Xingchen Peng

Biography:
Xingchen Peng

M.D., Ph.D. Radiation Oncologist
Department of Head and Neck Cancer, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University
No.37 Guo Xue Xiang, Chengdu, Sichuan, 610041, P.R China
Phone number: (+86) 028-85164059
Fax number: (+86) 028-85164060.
E-mail: pxx2014@scu.edu.cn

Research Interests
Comprehensive Treatment of Nasopharyngeal Carcinoma
Intensity-Modulated Radiotherapy of Head and Neck Cancer
Education
May., 2016 - May., 2018, Radiation Oncology, Harvard Medical School- Massachusetts General Hospital, Post doctor
Sep., 2009 - Jun., 2012, Oncology, West China School of Medicine, Sichuan University, Doctor
Sep., 2006 - Jun., 2009, Oncology, West China School of Medicine, Sichuan University, Master
Sep., 2001 - Jun., 2006, Clinical medicine, Zunyi Medical School, Bachelor
Academic Appointments
Associate Professor and Master's Supervisor, Oncology, Department of Head and Neck Cancer, Cancer Center, West China Hospital, Sichuan University
Administrative Appointments
Committee Member, Committee of Precision Radiotherapy in Head and Neck Cancer, Chinese Society of Biomedical Engineering
Committee Member, Committee of Anti-Cancer Agent, Sichuan Anti-Cancer Association
Awards
35 under 35. One of the 35 Young Oncologists Under the Age of 35 with the Greatest Potential. Chinese Society of Clinical Oncology. 2017
Grants
Two Grants Supported by National Natural Sciences Foundation of China
Two Grants Supported by Science and Technology Department of Sichuan Province
Two Grants Supported by Chinese Society of Clinical Oncology
Publications
Twenty-Six Papers (First Author or Corresponding Author) in Science Citation Index
Two Monographs

Presentation(s):

Send Email for Xingchen Peng


Assets

MO_31_2728 - Evaluation of Induction Chemotherapy with EPF or TPF for Patients with Locally Advanced Nasopharyngeal Carcinoma



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Evaluation of Induction Chemotherapy with EPF or TPF for Patients with Locally Advanced Nasopharyngeal Carcinoma